rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2009-1153rsp-1067Research ArticleСтатьиArticlesКачество жизни больных ревматоидным артритом, получающих этанерцептQuality of life of patients with rheumatoid arthritis receiving etanerceptAmirdzanovaV NAmirdzanovaV N-KaigorodsevaE YKaigorodsevaE Y-SavenkovaN ASavenkovaN A-200915082009474№4 (2009)7376Copyright © Amirdzanova V.N., Kaigorodseva E.Y., Savenkova N.A., 20092009Amirdzanova V.N., Kaigorodseva E.Y., Savenkova N.A.Amirdzanova V.N., Kaigorodseva E.Y., Savenkova N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/1067

Ревматоидный артрит (РА) – наиболее частое аутоиммунное воспалительное заболевание суставов, приводящее к появлению костных эрозий, суставной деструкции и деформации суставов. Боль в суставах и ограничение объема движений оказывают существенное влияние на выполнение больны- ми действий в повседневной жизни, значительное ухудшая ее качество.Качество жизни (КЖ) – это интегральный показатель различных сфер функционирования чело- века, основанный на субъективном восприятии пациента, оцениваемый с помощью специально созданных опросников. Поскольку КЖ является многомерным понятием, то не существует единого инструмента для его оценки. Американская коллегия ревматологов (АКР) рекомендует в этих случаях применять комбинацию специфических и общих опросников. При ревматоидном артрите (РА) наиболее часто в клинических исследованиях используются специфический опросник HAQ (Health Assessment Questionnaire) [1] и общие опросники SF-36 (Medical Outcomes Study 36-Item Short Form) [2] и EQ-5D (Euro QOL) [3,4]. Они имеют хорошие психометрические характеристики: высокую надежность, валидность и чувствительность к изменениям в состоянии здоровья пациентов.

References<div><p>Fries J. F., Spitz P., Kraines R. G., Holman H. R. Measurement of patient outcome in arthtitis. Arthritis Rheum., 1980, 23, 2, 137-45</p><p>Ware J. E., Snow K. K., Kosinski M. et al. SF-36 Health Survey. Manual and Interpretation Guide. - MA: Boston, 1993; 143</p><p>The EuroQol group. EuroQol – a new facility for the measurement of health related quality of life. Health Policy, 1990, 16, 199-208</p><p>Hurst N. P., Jobanputra P., Hunter M et al. Validity of EuroQol – a generic health status instrument in patients with rheumatoid arthtitis. Br. J. Rheumatol., 1994, 33, 655-62</p><p>Kind P., Hardman G., Macran S. UK Population norms for EQ-5D. York, UK, Centre for Health Economics, University of York, 1999, report 172 76 6. ACR. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update, Arthritis Rheum., 2002, 46, 328-46</p><p>Bathon J. M., Martin R. W., Fleischmann R. M. et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med., 2000, 343, 1586-93</p><p>Genovese M. E., Kremer J. M., Bankhurst A. D. et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiograhhic and clinical outcomes. Arthritis Rheum., 2002, 46, 1443-50</p><p>Cohen J. D., Zaltni S., Kaiser M. J. et al. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis. Ann. Rheum. Dis., 2004, 63, 209-10</p><p>Moreland L. W., Baumgartner S. W., Schiff M. H. et al. Treatment of rheumatoid arthritis with a recombinant humor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med., 1997, 337, 141-7</p><p>Moreland L. W., Schiff M. N., Baumgartner S. W. et al. Etanercept therapy in rheumatoid arthritis: randomized, controlled trial. Ann. Intern. Med., 1999, 130, 478-86</p><p>Weinblatt M. E., Kremer J. M., Bankhurst A. D. et al. A trial of etanercept, a recombinant tumor necrosis factor receptor; Fc fusion protein, in patients with rheumatoid arthritis receiving metotrexate. N. Engl. J. Med., 1999, 340, 253-59</p><p>Klareskog L., van der Heijde D. M., de Jager J. P. for the TEMPO Study Investigation. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheu- matoid arthritis: double-blind randomized controlled trial. Lancet, 2004, 363, 675-81</p><p>Burmester GR, Matucci Cerinic M., Mariette X. et al. Adalimumab effective and safe in treating RA in real life clinical practice: Final summary of the 6610 patients in REACT study. EULAR 2006, Amsterdam, THU0213</p><p>Сombe B., Codreanu C., Fiocco U. Et al. Etanercept and sulfasalazine, alone and combaned, in patients with active rheumatoid arthritis despite receiving sulfasalazine : a double-blind comparison. Ann. Rheum. Dis., 2006, 65, 1357-62</p><p>van Riel P. L. C., Taggat A. J., Sany J. et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with inadequate response to methotrexate: the ADOBE study. Ann. Rheum. Dis., 2006, 65, 1478-83</p><p>van Riel P. L. C., Freundlich B., MacPeek D. et al. Patient-reported outcome in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis:the ADOBE trial. Ann. Rheum. Dis., 2008, 67, 1104-10</p><p>Baumgartner S. W., Fleischmann R. M., Moreland L. W. et al. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus estanlished disease improvement in disability. J. Rheumatol., 2004, 31, 1532-57</p><p>Anis A., Zhang W., Emery P. et al. Work–related outcome in early active rheumatoid arthritis: results from the COMET trial. Ann. Rheum. Dis., 2008, 67 (suppl. II), 79</p><p>Weinblatt M. E., Schiff M. N., Ruderman E. M. et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week. Arthritis Rheum., 2008, 58, 1921-30</p><p>Мoots R., Cerinic M. M., Scaeverbeke T. et al. Anti-TNF drug utilization and Dosing patterns Assessment: a Retrospective chart Review study of subhects Treated for rgeumatoid arthritis (DART STUDY), 2008, Congress of British Society of Rheumatologist.</p></div><br /><div><p>Fries J. F., Spitz P., Kraines R. G., Holman H. R. Measurement of patient outcome in arthtitis. Arthritis Rheum., 1980, 23, 2, 137-45</p><p>Ware J. E., Snow K. K., Kosinski M. et al. SF-36 Health Survey. Manual and Interpretation Guide. - MA: Boston, 1993; 143</p><p>The EuroQol group. EuroQol – a new facility for the measurement of health related quality of life. Health Policy, 1990, 16, 199-208</p><p>Hurst N. P., Jobanputra P., Hunter M et al. Validity of EuroQol – a generic health status instrument in patients with rheumatoid arthtitis. Br. J. Rheumatol., 1994, 33, 655-62</p><p>Kind P., Hardman G., Macran S. UK Population norms for EQ-5D. York, UK, Centre for Health Economics, University of York, 1999, report 172 76 6. ACR. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update, Arthritis Rheum., 2002, 46, 328-46</p><p>Bathon J. M., Martin R. W., Fleischmann R. M. et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med., 2000, 343, 1586-93</p><p>Genovese M. E., Kremer J. M., Bankhurst A. D. et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiograhhic and clinical outcomes. Arthritis Rheum., 2002, 46, 1443-50</p><p>Cohen J. D., Zaltni S., Kaiser M. J. et al. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis. Ann. Rheum. Dis., 2004, 63, 209-10</p><p>Moreland L. W., Baumgartner S. W., Schiff M. H. et al. Treatment of rheumatoid arthritis with a recombinant humor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med., 1997, 337, 141-7</p><p>Moreland L. W., Schiff M. N., Baumgartner S. W. et al. Etanercept therapy in rheumatoid arthritis: randomized, controlled trial. Ann. Intern. Med., 1999, 130, 478-86</p><p>Weinblatt M. E., Kremer J. M., Bankhurst A. D. et al. A trial of etanercept, a recombinant tumor necrosis factor receptor; Fc fusion protein, in patients with rheumatoid arthritis receiving metotrexate. N. Engl. J. Med., 1999, 340, 253-59</p><p>Klareskog L., van der Heijde D. M., de Jager J. P. for the TEMPO Study Investigation. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheu- matoid arthritis: double-blind randomized controlled trial. Lancet, 2004, 363, 675-81</p><p>Burmester GR, Matucci Cerinic M., Mariette X. et al. Adalimumab effective and safe in treating RA in real life clinical practice: Final summary of the 6610 patients in REACT study. EULAR 2006, Amsterdam, THU0213</p><p>Сombe B., Codreanu C., Fiocco U. Et al. Etanercept and sulfasalazine, alone and combaned, in patients with active rheumatoid arthritis despite receiving sulfasalazine : a double-blind comparison. Ann. Rheum. Dis., 2006, 65, 1357-62</p><p>van Riel P. L. C., Taggat A. J., Sany J. et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with inadequate response to methotrexate: the ADOBE study. Ann. Rheum. Dis., 2006, 65, 1478-83</p><p>van Riel P. L. C., Freundlich B., MacPeek D. et al. Patient-reported outcome in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis:the ADOBE trial. Ann. Rheum. Dis., 2008, 67, 1104-10</p><p>Baumgartner S. W., Fleischmann R. M., Moreland L. W. et al. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus estanlished disease improvement in disability. J. Rheumatol., 2004, 31, 1532-57</p><p>Anis A., Zhang W., Emery P. et al. Work–related outcome in early active rheumatoid arthritis: results from the COMET trial. Ann. Rheum. Dis., 2008, 67 (suppl. II), 79</p><p>Weinblatt M. E., Schiff M. N., Ruderman E. M. et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week. Arthritis Rheum., 2008, 58, 1921-30</p><p>Мoots R., Cerinic M. M., Scaeverbeke T. et al. Anti-TNF drug utilization and Dosing patterns Assessment: a Retrospective chart Review study of subhects Treated for rgeumatoid arthritis (DART STUDY), 2008, Congress of British Society of Rheumatologist.</p></div><br />

The authors declare that there are no conflicts of interest present.